This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert J. Hardy, PhD
Houston, Tex

Earl A. Palmer, MD
Portland, Ore

John T. Flynn, MD
Miami, Fla

Arch Ophthalmol. 1995;113(6):698.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In reply

For years, the Multicenter Trial of Cryotherapy for ROP investigators have devoted countless hours to studying the relation between stage 3 ROP and eventual outcome. The risk for an unfavorable outcome depends on multiple variables, only one of which is the extent of stage 3 disease. A more posterior location (zone) of ROP and the presence of plus disease are important indexes of ROP severity. Rapidity of disease progression is also significant.¹

The requested subgrouping of fundus outcome data shows no significant difference in the rate of occurrence of unfavorable outcome (P=.65) across the 4 clock hours of ROP. The lowest rate of unfavorable fundus outcome, 6.1%, was for eyes with 4 clock hours of stage 3 ROP, and the highest rate, 15.7%, was for eyes with 3 clock hours.

In response to Dr Hindle, there is probably no perfect way to ensure against adverse outcomes . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?